Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib + GEMOX for first-line advanced biliary tract malignancies
ChiCTR2400085775Phase 2Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jun 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, Rivoceranib, gemcitabine and oxaliplatin in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: 6-month progression-free survival rate. Started Jun 2024; status: recruiting.
02
Drugs
camrelizumabRivoceranibgemcitabineoxaliplatin
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2400085775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085775.